Author: uwg2609@mail.de

Chapter 2: Preclinical Development – Alchemists, Animals, and PK/PD Models Pfizer’s goal was ambitious. The new compound had to accomplish several things at once. It needed to inhibit virtually all known resistance mutations of both ALK and ROS1 while at the same time providing better control of brain metastases than the available second-generation ALK inhibitors….

Chapter 1 – How It All Began In 2007, Japanese researchers made a discovery that fundamentally changed the treatment of a small subgroup of patients with non-small cell lung cancer (NSCLC). They identified rearrangements involving the anaplastic lymphoma kinase (ALK) gene—today commonly referred to as ALK rearrangements, ALK translocations, or simply ALK fusions. For the…